Document Type : Research Articles
Procédés de criblage moléculaire et cellulaire, Centre of Biotechnology of Sfax B.P K.3038 Sfax, Tunisia.
Patholab Private CytoPathology Laboratory R. du Caire, Cité Jardin Sfax,Tunisia.
Patholab Private Cytopathology Laboratory A. Ibn Khaldoun Sfax, Tunisia.
Patholab Private Cytopathology Laboratory Dar elhkim route touristique 4190 homtessouk, Djerba,Tunisia.
Laboratoire d’anatomie et de cytologie pathologique, EPS Farhat Hached Hospital, Sousse,Tunisia.
Background: Breast cancers are heterogeneous, making it essential to recognize several biomarkers for cancer
outcome predictions especially in young women where the classical prediction parameters are not suitable. The goal
from this study is to evaluate the impact of B cell lymphoma 2 (BCL2), P53 and Ki-67 proteins expression on survival
in young women patients with invasive ductal carcinoma. Patients and methods: Samples and clinical data from 238
patients were collected between 2003 and 2017. They were selected according to 2 criteria: age ≤40 years old and most of
them are affected by an Invasive Ductal Carcinoma. We evaluated BCL2, P53 and ki-67 expression by immunochemistry
test, and then we assessed correlations of these biomarkers expression with patient’s clinicopathological characteristics
and survival. Results: Triple negative breast cancer group showed a high frequency among our cohort but we emphasize
an almost equitable distribution among all molecular groups. Contrary to other studies which reported that luminal A
was correlated with better prognosis, our analysis demonstrated that luminal A is correlated with the Scarff, Bloom
and Richardson (SBR) grading 2 or SBR grading 3. To better investigate the prognosis, we analyze three biomarkers
known by their impact on physiopathology behavior on breast cancer BCL2, ki-67and P53. BCL2 is the more relevant
one, it was correlated with molecular subtypes (p=0.0012) and SBR grading (p=0.0016). BCL2 seems to be the good
prognostic biomarker related to survival (p=0.004) with a protective role among patients when endocrine therapy
is not provided and Lymph Node (LN) involvement is positive (p=0.021, p=0.000 respectively). Conclusions: The
classical prognostic parameters based mainly on the molecular classification in breast cancer seem insufficient in the
case of young women. BCL2 protein expression analysis provides a better prognostic value. BCL2 should be clinically
associated in current practice when young women specimens are diagnosticated.